Association of in vivo retention of [
AT8
Alzheimer’s disease
Flortaucipir
Neuropathology
PET
Tau
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
14
06
2024
accepted:
06
09
2024
revised:
05
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
epublish
Résumé
[
Identifiants
pubmed: 39297933
doi: 10.1007/s00401-024-02801-2
pii: 10.1007/s00401-024-02801-2
doi:
Substances chimiques
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
J09QS3Z3WB
Carbolines
0
tau Proteins
0
Radiopharmaceuticals
0
MAPT protein, human
0
Fluorine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Subventions
Organisme : H2020 European Research Council
ID : ADG-101096455
Organisme : Alzheimer's Association
ID : ZEN24-1069572
Pays : United States
Organisme : Alzheimer's Association
ID : SG-23-1061717
Pays : United States
Organisme : Vetenskapsrådet
ID : 2022-00775
Organisme : ERA PerMed
ID : ERAPERMED2021-184
Organisme : Knut och Alice Wallenbergs Stiftelse
ID : 2022-0231
Organisme : Alzheimerfonden
ID : AF-980907
Organisme : Alzheimerfonden
ID : AF-939981
Organisme : Hjärnfonden
ID : FO2021-0293
Organisme : Parkinsonfonden
ID : 1412/22
Organisme : Skånes universitetssjukhus
ID : 2020-O000028
Organisme : Regionalt Forskningsstöd
ID : 2022-1259
Organisme : Regionalt Forskningsstöd
ID : 2021-1013
Organisme : Swedish federal government under the ALF agreement
ID : 2022-Projekt0080
Organisme : Swedish federal government under the ALF agreement
ID : 2020-YF0020
Informations de copyright
© 2024. The Author(s).
Références
Avants B, Tustison NJ, Song G (2009) Advanced normalization tools V1.0. Insight J. https://doi.org/10.54294/uvnhin
doi: 10.54294/uvnhin
Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG et al (2015) Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology 35:354–389. https://doi.org/10.1111/neup.12189
doi: 10.1111/neup.12189
pubmed: 25619230
pmcid: 4593391
Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61:378–384. https://doi.org/10.1001/archneur.61.3.378
doi: 10.1001/archneur.61.3.378
pubmed: 15023815
Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD et al (2018) [(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry 89:1032–1037. https://doi.org/10.1136/jnnp-2017-316402
doi: 10.1136/jnnp-2017-316402
pubmed: 28912300
Boykov Y, Kolmogorov V (2004) An experimental comparison of min-cut/max-flow algorithms for energy minimization in vision. IEEE Trans Pattern Anal Mach Intell 26:1124–1137. https://doi.org/10.1109/tpami.2004.60
doi: 10.1109/tpami.2004.60
pubmed: 15742889
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. https://doi.org/10.1007/bf00308809
doi: 10.1007/bf00308809
pubmed: 1759558
Carlos AF, Tosakulwong N, Weigand SD, Senjem ML, Schwarz CG, Knopman DS et al (2023) TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer’s disease. Alzheimers Dement 19:2343–2354. https://doi.org/10.1002/alz.12878
doi: 10.1002/alz.12878
pubmed: 36463537
Costoya-Sánchez A, Moscoso A, Silva-Rodríguez J, Pontecorvo MJ, Devous MD Sr, Aguiar P et al (2023) Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-β positivity. JAMA Neurol 80:1051–1061. https://doi.org/10.1001/jamaneurol.2023.2560
doi: 10.1001/jamaneurol.2023.2560
pubmed: 37578787
pmcid: 10425864
Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I et al (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128:755–766. https://doi.org/10.1007/s00401-014-1349-0
doi: 10.1007/s00401-014-1349-0
pubmed: 25348064
pmcid: 4257842
Dickson DW (2005) Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol 109:14–24. https://doi.org/10.1007/s00401-004-0950-z
doi: 10.1007/s00401-004-0950-z
pubmed: 15645265
Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157. https://doi.org/10.1016/S1474-4422(09)70238-8
doi: 10.1016/S1474-4422(09)70238-8
pubmed: 19909913
Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP et al (2020) Positron Emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer Disease neuropathologic changes. JAMA Neurol 77:829–839. https://doi.org/10.1001/jamaneurol.2020.0528
doi: 10.1001/jamaneurol.2020.0528
pubmed: 32338734
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39. https://doi.org/10.1001/archneur.56.1.33
doi: 10.1001/archneur.56.1.33
pubmed: 9923759
Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R (2022) Tau PET imaging in neurodegenerative disorders. J Nucl Med 63:20s–26s. https://doi.org/10.2967/jnumed.121.263196
doi: 10.2967/jnumed.121.263196
pubmed: 35649647
Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954–963. https://doi.org/10.1038/s41591-021-01382-x
doi: 10.1038/s41591-021-01382-x
pubmed: 34083813
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007
doi: 10.1016/j.jalz.2011.10.007
pubmed: 22265587
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS et al (2017) Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement 13:205–216. https://doi.org/10.1016/j.jalz.2016.08.005
doi: 10.1016/j.jalz.2016.08.005
pubmed: 27697430
Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR et al (2014) Staging TDP-43 pathology in Alzheimer’s disease. Acta Neuropathol 127:441–450. https://doi.org/10.1007/s00401-013-1211-9
doi: 10.1007/s00401-013-1211-9
pubmed: 24240737
Josephs KA, Tosakulwong N, Weigand SD, Graff-Radford J, Schwarz CG, Senjem ML et al (2024) Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age-related tauopathy and Alzheimer’s disease. Sci Transl Med 16:8076. https://doi.org/10.1126/scitranslmed.ado8076
doi: 10.1126/scitranslmed.ado8076
Kuijf HJ, Biesbroek JM, Viergever MA, Biessels GJ, Vincken KL (2013) Registration of brain CT images to an MRI template for the purpose of lesion-symptom mapping. Springer International Publishing, pp 119–128
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E et al (2019) Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry 24:1112–1134. https://doi.org/10.1038/s41380-018-0342-8
doi: 10.1038/s41380-018-0342-8
pubmed: 30635637
pmcid: 6756230
Leuzy A, Pascoal TA, Strandberg O, Insel P, Smith R, Mattsson-Carlgren N et al (2021) A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. Eur J Nucl Med Mol Imaging 48:2295–2305. https://doi.org/10.1007/s00259-021-05401-4
doi: 10.1007/s00259-021-05401-4
pubmed: 34041562
pmcid: 8175317
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE et al (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58. https://doi.org/10.1186/s40478-016-0315-6
doi: 10.1186/s40478-016-0315-6
pubmed: 27296779
pmcid: 4906968
Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA et al (2020) Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement 16:561–571. https://doi.org/10.1016/j.jalz.2019.09.079
doi: 10.1016/j.jalz.2019.09.079
pubmed: 31784374
Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113. https://doi.org/10.1007/s00401-011-0845-8
doi: 10.1007/s00401-011-0845-8
pubmed: 21644037
pmcid: 3285143
Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A et al (2018) Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry 89:1024–1031. https://doi.org/10.1136/jnnp-2017-316409
doi: 10.1136/jnnp-2017-316409
pubmed: 28986472
Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800. https://doi.org/10.1002/ana.24517
doi: 10.1002/ana.24517
pubmed: 26344059
pmcid: 4900162
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872. https://doi.org/10.1212/01.wnl.0000187889.17253.b1
doi: 10.1212/01.wnl.0000187889.17253.b1
pubmed: 16237129
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al (1991) The consortium to establish a registry for Alzheimer’s disease (CERAD). part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486. https://doi.org/10.1212/wnl.41.4.479
doi: 10.1212/wnl.41.4.479
pubmed: 2011243
Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11. https://doi.org/10.1007/s00401-011-0910-3
doi: 10.1007/s00401-011-0910-3
pubmed: 22101365
Ossenkoppele R, Reimand J, Smith R, Leuzy A, Strandberg O, Palmqvist S et al (2021) Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med 13:e14398. https://doi.org/10.15252/emmm.202114398
doi: 10.15252/emmm.202114398
pubmed: 34254442
pmcid: 8350902
Pontecorvo MJ, Keene CD, Beach TG, Montine TJ, Arora AK, Devous MD Sr et al (2020) Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study. EJNMMI Res 10:65. https://doi.org/10.1186/s13550-020-00653-x
doi: 10.1186/s13550-020-00653-x
pubmed: 32542468
pmcid: 7295920
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 43:250–260. https://doi.org/10.1212/wnl.43.2.250
doi: 10.1212/wnl.43.2.250
pubmed: 8094895
Seshadri S, Wolf PA (2007) Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol 6:1106–1114. https://doi.org/10.1016/s1474-4422(07)70291-0
doi: 10.1016/s1474-4422(07)70291-0
pubmed: 18031707
Smith R, Santillo AF, Waldö ML, Strandberg O, Berron D, Vestberg S et al (2019) (18)F-flortaucipir in TDP-43 associated frontotemporal dementia. Sci Rep 9:6082. https://doi.org/10.1038/s41598-019-42625-9
doi: 10.1038/s41598-019-42625-9
pubmed: 30988363
pmcid: 6465310
Smith R, Wibom M, Pawlik D, Englund E, Hansson O (2019) Correlation of In Vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol 76:310–317. https://doi.org/10.1001/jamaneurol.2018.3692
doi: 10.1001/jamaneurol.2018.3692
pubmed: 30508025
Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL et al (2020) 18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases. Brain 143:3477–3494. https://doi.org/10.1093/brain/awaa276
doi: 10.1093/brain/awaa276
pubmed: 33141172
pmcid: 7719031
Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800. https://doi.org/10.1212/wnl.58.12.1791
doi: 10.1212/wnl.58.12.1791
pubmed: 12084879
Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V et al (2019) (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther 11:13. https://doi.org/10.1186/s13195-019-0470-7
doi: 10.1186/s13195-019-0470-7
pubmed: 30704514
pmcid: 6357510
Weigand AJ, Edwards LE, Thomas KR, Bangen KJ, Bondi MW (2022) Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta. Brain Commun 4:fcac272. https://doi.org/10.1093/braincomms/fcac272
doi: 10.1093/braincomms/fcac272
pubmed: 36382220
pmcid: 9651027
Whitwell JL, Ahlskog JE, Tosakulwong N, Senjem ML, Spychalla AJ, Petersen RC et al (2018) Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer’s disease in progressive supranuclear palsy. Parkinsonism Relat Disord 48:3–9. https://doi.org/10.1016/j.parkreldis.2017.12.016
doi: 10.1016/j.parkreldis.2017.12.016
pubmed: 29254665
Whitwell JL, Martin PR, Duffy JR, Clark HM, Machulda MM, Schwarz CG et al (2019) The influence of β-amyloid on [(18)F]AV-1451 in semantic variant of primary progressive aphasia. Neurology 92:e710–e722. https://doi.org/10.1212/wnl.0000000000006913
doi: 10.1212/wnl.0000000000006913
pubmed: 30635491
pmcid: 6382367